Exacerbation of myasthenia gravis after removal of thymomas.
It appeared from this prospective and non-randomized study, that the removal of thymomas in myasthenia gravis (MG) patients resulted in rapid exacerbation of the clinical severity of the disease and of anti-acetylcholine receptor antibodies titres, which peaked after about 300 days and continued for up to 2 years. Long-term follow-up after thymomectomy (mean duration +/- SEM after surgery 5.5 +/- 0.8 years) showed that the immunological and clinical state observed prior to surgery was eventually restored, but long-term benefit attributable to surgery could not be demonstrated. Non-thymoma MG cases, however, exhibited post-operative amelioration in clinical course and decreasing antibodies titres, both of which were already significant one year after surgery, and additional improvement was observed at the time of long-term follow-up (mean 4.3 +/- 0.5 years). Furthermore, the prognosis for MG patients not operated on was also favourable. It is suggested that the occurrence of thymomas is linked to genetic factors and that neoplasia of the thymus may be part of immunoregulatory mechanisms with predominance of inhibition.
Somnier
F E
FE
Department of Neurology, National Hospital (Rigshospitalet), Hellerup, Denmark.
D000293:Adolescent; D000328:Adult; D000906:Antibodies / Q000032:analysis; D001327:Autoimmune Diseases / Q000276:immunology*; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008875:Middle Aged; D009157:Myasthenia Gravis / Q000276:immunology*; D011379:Prognosis; D011446:Prospective Studies; D011863:Radioimmunoassay; D011950:Receptors, Cholinergic / Q000276:immunology; D013934:Thymectomy / Q000009:adverse effects*; D013945:Thymoma / Q000276:immunology* / Q000601:surgery*; D013953:Thymus Neoplasms / Q000276:immunology* / Q000601:surgery*
D000906:Antibodies; D011950:Receptors, Cholinergic